Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review. [PDF]
HeadacheAbstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Hyland AC +7 more
europepmc +2 more sources
Post Hoc Subgroup Analyses of the Efficacy and Safety of Zavegepant for the Acute Treatment of Migraine According to Baseline Triptan Experience [PDF]
Journal of Pain ResearchJelena M Pavlovic,1 Richard B Lipton,1 Shivang Joshi,2 Robert Fountaine,3 Linda O Mosher41Department of Neurology and Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Headache Medicine, Community ...
Pavlovic JM +4 more
doaj +2 more sources
A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy [PDF]
Journal of Pain ResearchNuo Xu,1 Xiaowen Lu2 1Department of Clinical Nutrition, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China; 2Department of Neurosurgery, The First Affiliated Hospital of Shantou University ...
Xu N, Lu X
doaj +2 more sources
Managing migraine with over-the-counter provision of triptans: the perspectives and readiness of Western Australian community pharmacists [PDF]
PeerJ, 2019 Background Down-scheduling one or more triptans to Schedule 3 (Pharmacist Only Medicine) from Schedule 4 (Prescription Only Medicine) has been debated in Australia for a decade.
Shaid Booth +3 more
doaj +2 more sources
Scientific Reports, 2021 Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains.
Anick Bérard +4 more
doaj +1 more source
Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms
Scientific Reports, 2023 Migraine is a common, polygenic disorder that is characterized by moderate to severe headache attacks. Migraine attacks are commonly treated with triptans, i.e. serotonin receptor agonists.
Lisette J. A. Kogelman +10 more
doaj +1 more source
The Journal of Headache and Pain, 2023 Background Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans ...
Ruth Ruscheweyh +11 more
doaj +1 more source
Association between response to triptans and response to erenumab: real-life data
The Journal of Headache and Pain, 2021 Background Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab.
Ilaria Frattale +14 more
doaj +1 more source
Headache in daily practice: What a physician needs to know
APIK Journal of Internal Medicine, 2021 Headache is a common presenting complaint encountered in the outpatient as well as inpatient settings. Appropriate diagnosis and treatment of the commonly encountered primary headaches, timely evaluation for secondary causes, and patient education are ...
Pooja Mailankody +2 more
doaj +1 more source
NSAIDs and Triptans – a (not) New Treatment Option for Migraine
Neurologijos seminarai, 2023 Every day, around 7% of population will experience headache caused by migraine. Migraine is one of the leading causes of years lived with disability, and it also causes significant negative economic impact, as most as the affected population is of ...
B. Kakta, Rasa Mameniškienė
doaj +3 more sources